Business
SciSparc Signs Clinical Trial Agreement with Yale University to Conduct its Phase IIb Trial in Tourette Syndrome
The addition of a U.S. site will allow SciSparc to accelerate trial recruitment and further development of novel treatments for patients in need TEL AVIV,
About this update from Scisparc Ltd.
[{"type":"text","content":"The addition of a U.S. site will allow SciSparc to accelerate trial recruitment and further development of novel treatments for patients in need TEL AVIV, Israel, Aug. 01, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (\"Company\" or \"SciSparc\"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced the addition of another site of excellence, the Yale Child Study Center at Yale University, to its Phase IIb clinical trial for SCI-110 in patients suffering from Tourette Syndrome (\"TS\"). The trial will be led by Dr. Michael H. Bloch, M.D., M.S., an associate Professor in the Child Study Center at Yale University and a leading researcher in the field of TS. Yale University is the third medical center to join SciSparc’s multi-national, multi-center trial. Previously, SciSparc announced the Hannover Medical School in Hannover, Germany, and the Tel Aviv Sourasky Medical Center in Tel Aviv, Israel as medical center trial sites of excellence. “We are very excited about the opportunity to return and collaborate with Dr. Bloch and his team at Yale University. We see this as an expression of confidence in the potential of the drug we are developing for the treatment of Tourette’s patients,\" commented Dr. Adi Zuloff-Shani, SciSparc’ s Chief Technologies Officer. \"Importantly, this Phase IIb trial is a unified trial, as the trial’s data are expected to qualify for regulatory submissions with both the FDA (U.S. Federal Drug Administration) and the EMA (European Medicines Agency). We look forward to further expanding this trial, as part of the overall team effort working to develop a treatment for this therapeutic area, which is greatly underserved, and we believe our approach has significant advantages over available treatments.” TS is a movement and neurobehavioral disorder characterized by chronic motor and vocal tics. With onset before age 18, about half to two-thirds of TS cases improve during adolescence, while adults are generally more severe patients. Tic symptoms are prevalent in TS cases and may be associated with a premonitory sensation to perform a specific action, which may lead to “relief” once performed. Previously, a Phase IIa trial, conducted at the same site at Yale University, showed that trial patients, which ...